GlassScriptPhysician profile
Pavel Mudrenko
NPI 1487402251
$660.96
in general payments reported to CMS, 2019-2025
13 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $88.67 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $157.96 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $114.51 | 2024-2025 | Verquvo |
| Amgen INC. | $106.71 | 2024-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $43.23 | 2025 | Wainua, Farxiga |
| Boston Scientific Corporation | $40.86 | 2025 | Watchman Flx |
| Novo Nordisk INC | $36.14 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $34.12 | 2025 | Amvuttra |
| United Therapeutics Corporation | $31.87 | 2025 | Tyvaso |
| Glaxosmithkline, LLC. | $22.88 | 2025 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $18.71 | 2025 | |
| Kestra Medical Technology Services, INC. | $18.21 | 2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $18.09 | 2025 | Camzyos |
| Lilly USA, LLC | $17.67 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavel Mudrenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.